Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essenti...
Uloženo v:
| Médium: | Elektronický zdroj E-kniha |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
Cham :
Springer International Publishing,
2018.
|
| Vydání: | 1st ed. 2018. |
| Edice: | Resistance to Targeted Anti-Cancer Therapeutics,
15 |
| Témata: | |
| ISBN: | 9783319679327 |
| ISSN: | 2196-5501 ; |
| On-line přístup: |
|
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 003 | SK-BrCVT | ||
| 005 | 20220618101632.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 180328s2018 gw | s |||| 0|eng d | ||
| 020 | |a 9783319679327 | ||
| 024 | 7 | |a 10.1007/978-3-319-67932-7 |2 doi | |
| 035 | |a CVTIDW13620 | ||
| 040 | |a Springer-Nature |b eng |c CVTISR |e AACR2 | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways |h [electronic resource] / |c edited by Yosef Yarden, Moshe Elkabets. |
| 250 | |a 1st ed. 2018. | ||
| 260 | 1 | |a Cham : |b Springer International Publishing, |c 2018. | |
| 300 | |a XX, 242 p. 22 illus. in color. |b online resource. | ||
| 490 | 1 | |a Resistance to Targeted Anti-Cancer Therapeutics, |x 2196-5501 ; |v 15 | |
| 500 | |a Biomedical and Life Sciences | ||
| 505 | 0 | |a Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis. | |
| 516 | |a text file PDF | ||
| 520 | |a This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance. | ||
| 650 | 0 | |a Cancer research. | |
| 856 | 4 | 0 | |u http://hanproxy.cvtisr.sk/han/cvti-ebook-springer-eisbn-978-3-319-67932-7 |y Vzdialený prístup pre registrovaných používateľov |
| 910 | |b ZE10900 | ||
| 919 | |a 978-3-319-67932-7 | ||
| 974 | |a andrea.lebedova |f Elektronické zdroje | ||
| 992 | |a SUD | ||
| 999 | |c 237969 |d 237969 | ||